The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Prevalence of chronic obstructive pulmonary disease (COPD) and the disease's burden varies significantly by state.

Writing all this information down and using a COPD Action Plan, or keeping a journal is a great way to stay organized and reduce stress, especially in an emergency situation. Your notes should include ...

The FDA just gave the green light to Nucala (mepolizumab), a new medication that is now an official “add-on” treatment for adults battling chronic obstructive pulmonary disease (COPD) that just isn’t ...

A NEW study finds that machine learning models using data from digital inhalers can successfully predict chronic obstructive pulmonary disease (COPD) exacerbations up to 5 days in advance, offering a ...

Approximately 70% of COPD patients in the US who are inadequately controlled on inhaled triple therapy and continue to exacerbate have a BEC starting at 150 cells/μL and above.4,5 This represents over ...

The FDA’s approval of Nucala in COPD was based on data from the MATINEE and METREX phase 3 trials. These trials assessed Nucala 100 mg as add-on therapy, administered subcutaneously every four weeks ...

COPD affects around 1.2 million people in the UK and is the second most common cause of emergency hospital admissions. Trixeo Aerosphere is used to make breathing easier and improve symptoms of COPD ...

COPD treatment involves a variety of approaches, from medications to lifestyle adjustments. Bronchodilators are commonly prescribed to help relax the muscles around the airways and make it easier ...

Ms Bishop asked that people who use inhalers bring them along “so we can show them how to best use them and check that they're on the right medications”. The COPD fair will run from 12pm to ...

BOSTON — Patients with COPD faced a decreased risk of severe cardiopulmonary events if treated with single inhaler vs. multiple inhaler triple therapy, according to data presented at the CHEST ...